ProShares Ultra Nasdaq Biotechnology seeks to provide daily investment results that correspond to two times the daily performance of the Nasdaq Biotechnology Index. Now — the numbers.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
It pays out $0.49 per share each year — regular cash for whoever holds the stock.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 6/100.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.